Robert Schwarcz

Dr. Robert Schwarcz

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 July 2017 in Neuropharmacology
Verified
Journal Article
Closed access
DBD.M. Bortz
D.M. Bortz
HWH.-Q. Wu
H.-Q. Wu
RSRobert Schwarcz
Robert Schwarcz
JBJ.P. Bruno
J.P. Bruno

1 January 1997 in European Journal of Pharmacology
Verified
Journal Article
Closed access
HWHui-Qiu Wu
Hui-Qiu Wu
FSFrancesco G. Salituro
Francesco G. Salituro
RSRobert Schwarcz
Robert Schwarcz

5 August 2020 in Neuroscience
Verified
Journal Article
Closed access
TBT. Blanco-Ayala
T. Blanco-Ayala
KSK.V. Sathyasaikumar
K.V. Sathyasaikumar
JUJ.D. Uys
J.D. Uys
VPV. Pérez-De-La-Cruz
V. Pérez-De-La-Cruz
LPL.S. Pidugu
L.S. Pidugu
RSRobert Schwarcz
Robert Schwarcz

20 January 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
TATonali Blanco Ayala
Tonali Blanco Ayala
DODANIELA RAMIREZ ORTEGA
DANIELA RAMIREZ ORTEGA
PRPaulina Ovalle Rodríguez
Paulina Ovalle Rodríguez
BPBENJAMIN PINEDA
BENJAMIN PINEDA
GCGonzalo Pérez de la Cruz
Gonzalo Pérez de la Cruz
Veronica Perez-De la CruzVeronica Perez-De la Cruz
Veronica Perez-De la Cruz
The tryptophan (Trp) metabolite kynurenic acid (KYNA) is an α7-nicotinic and N-methyl-d-aspartate receptor antagonist. Elevated brain KYNA levels are commonly seen in psychiatric disorders and neurodegenerative diseases and may be related to cognitive impairments. Recently, we showed that N-acetylcysteine (NAC) inhibits kynurenine aminotransferase II (KAT II), KYNA’s key biosynthetic enzyme, and reduces KYNA neosynthesis in rats in vivo. In this study, we examined if repeated systemic administration of NAC influences brain KYNA and cognitive performance in mice. Animals received NAC (100 mg/kg, i.p.) daily for 7 days. Redox markers, KYNA levels, and KAT II activity were determined in the brain. We also assessed the effect of repeated NAC treatment on Trp catabolism using brain tissue slices ex vivo. Finally, learning and memory was evaluated with and without an acute challenge with KYNA’s bioprecursor L-kynurenine (Kyn; 100 mg/kg). Subchronic NAC administration protected against an acute pro-oxidant challenge, decreased KYNA levels, and lowered KAT II activity and improved memory both under basal conditions and after acute Kyn treatment. In tissue slices from these mice, KYNA neosynthesis from Trp or Kyn was reduced. Together, our data indicate that prolonged treatment with NAC may enhance memory at least in part by reducing brain KYNA levels.

4 February 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
Korrapati V. SathyasaikumarKorrapati V. Sathyasaikumar
Korrapati V. Sathyasaikumar
Veronica Perez-De la CruzVeronica Perez-De la Cruz
Veronica Perez-De la Cruz
BPBENJAMIN PINEDA
BENJAMIN PINEDA
GCGustavo Ignacio Vázquez Cervantes
Gustavo Ignacio Vázquez Cervantes
DODANIELA RAMIREZ ORTEGA
DANIELA RAMIREZ ORTEGA
RSRobert Schwarcz
Robert Schwarcz
Kynurenine 3-monooxygenase (KMO), a key player in the kynurenine pathway (KP) of tryptophan degradation, regulates the synthesis of the neuroactive metabolites 3-hydroxykynurenine (3-HK) and kynurenic acid (KYNA). KMO activity has been implicated in several major brain diseases including Huntington’s disease (HD) and schizophrenia. In the brain, KMO is widely believed to be predominantly localized in microglial cells, but verification in vivo has not been provided so far. Here, we examined KP metabolism in the brain after depleting microglial cells pharmacologically with the colony stimulating factor 1 receptor inhibitor PLX5622. Young adult mice were fed PLX5622 for 21 days and were euthanized either on the next day or after receiving normal chow for an additional 21 days. Expression of microglial marker genes was dramatically reduced on day 22 but had fully recovered by day 43. In both groups, PLX5622 treatment failed to affect Kmo expression, KMO activity or tissue levels of 3-HK and KYNA in the brain. In a parallel experiment, PLX5622 treatment also did not reduce KMO activity, 3-HK and KYNA in the brain of R6/2 mice (a model of HD with activated microglia). Finally, using freshly isolated mouse cells ex vivo, we found KMO only in microglia and neurons but not in astrocytes. Taken together, these data unexpectedly revealed that neurons contain a large proportion of functional KMO in the adult mouse brain under both physiological and pathological conditions.